Alliancebernstein L.P. Intellia Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 2,193,787 shares of NTLA stock, worth $20.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,193,787

Previous 1,782,884 23.05%

Holding current value

$20.8 Million

Previous $39.9 Million 12.99%

% of portfolio

0.02%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $8.1 Million - $11.2 Million	410,903 Added 23.05%	2,193,787 $45.1 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $4.23 Million - $5.75 Million	211,360 Added 13.45%	1,782,884 $39.9 Million
Q1 2024 May 14, 2024	SELL	$23.82 - $32.8 $2.2 Million - $3.02 Million	-92,218 Reduced 5.54%	1,571,524 $43.2 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $2.7 Million - $3.77 Million	116,630 Added 7.54%	1,663,742 $50.7 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $5.55 Million - $8.04 Million	-175,665 Reduced 10.2%	1,547,112 $48.9 Million
Q2 2023 Aug 15, 2023	SELL	$34.58 - $46.03 $1.46 Million - $1.94 Million	-42,151 Reduced 2.39%	1,722,777 $70.3 Million
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $2.5 Million - $3.37 Million	75,206 Added 4.45%	1,764,928 $65.8 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $8.88 Million - $16.8 Million	267,521 Added 18.81%	1,689,722 $59 Million
Q3 2022 Nov 15, 2022	SELL	$53.92 - $71.7 $15.2 Million - $20.3 Million	-282,450 Reduced 16.57%	1,422,201 $79.6 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $1.66 Million - $3.28 Million	-43,030 Reduced 2.46%	1,704,651 $88.2 Million
Q1 2022 May 13, 2022	BUY	$58.27 - $118.99 $16.6 Million - $33.9 Million	285,021 Added 19.49%	1,747,681 $127 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $22.7 Million - $31.2 Million	225,756 Added 18.25%	1,462,660 $173 Million
Q3 2021 Nov 10, 2021	BUY	$132.37 - $176.78 $3.63 Million - $4.85 Million	27,436 Added 2.27%	1,236,904 $166 Million
Q2 2021 Jul 30, 2021	SELL	$60.88 - $161.91 $33.4 Million - $88.8 Million	-548,344 Reduced 31.19%	1,209,468 $196 Million
Q1 2021 May 06, 2021	BUY	$46.59 - $83.68 $79 Million - $142 Million	1,695,712 Added 2730.62%	1,757,812 $141 Million
Q4 2020 Feb 08, 2021	BUY	$18.83 - $63.53 $9,415 - $31,765	500 Added 0.81%	62,100 $3.38 Million
Q3 2020 Nov 12, 2020	SELL	$17.47 - $24.93 $22,711 - $32,409	-1,300 Reduced 2.07%	61,600 $1.23 Million
Q2 2020 Aug 13, 2020	BUY	$11.14 - $22.87 $103,602 - $212,691	9,300 Added 17.35%	62,900 $1.32 Million
Q1 2019 May 14, 2019	SELL	$12.79 - $17.62 $66,508 - $91,624	-5,200 Reduced 8.84%	53,600 $915,000
Q2 2018 Aug 13, 2018	BUY	$20.02 - $30.79 $708,708 - $1.09 Million	35,400 Added 151.28%	58,800 $1.61 Million
Q1 2018 May 14, 2018	SELL	$19.43 - $34.95 $95,207 - $171,255	-4,900 Reduced 17.31%	23,400 $494,000
Q4 2017 Feb 13, 2018	BUY	$17.39 - $31.12 $20,868 - $37,344	1,200 Added 4.43%	28,300 $544,000
Q3 2017 Nov 13, 2017	BUY	$15.16 - $25.75 $410,836 - $697,825	27,100	27,100 $673,000

Others Institutions Holding NTLA

# of Institutions

316

Shares Held

91.7M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Intellia Therapeutics, Inc. Transaction History